Isola Capital Group

Isola Capital Group is a family office asset management platform based in Hong Kong, with an additional office in Belgium. Founded in 1946, the firm focuses on entrepreneurial and multi-asset class investments, including private equity, venture capital, and private credit. It specializes in mezzanine financing, pre-IPO investments, and various other financial instruments. Isola Capital Group operates through two main divisions: Isola Capital Partners, which targets direct investments in the Asia Pacific region, particularly in sectors such as education, healthcare, and premium consumer goods; and Isola Venture Partners, which invests globally in early-stage ventures across industries like EdTech, FinTech, and HealthTech. The firm aims to acquire either controlling or significant minority stakes in its investments, and also offers family office services including discretionary portfolio management and investment advisory. Isola is regulated by the Hong Kong Securities and Futures Commission.

Anthony Chan

CEO and Member of Advisory and Operating Committee

Kevin Tang

CFO

2 past transactions

Mezzofy

Seed Round in 2024
Mezzofy is a global digital coupon and voucher platform that enables businesses to create, distribute, redeem, track, and measure digital coupons efficiently. The platform serves as an all-in-one solution, having processed over 400 million coupons valued at more than $5 billion, and supports more than 13,000 outlets worldwide. Mezzofy caters to a diverse range of clients, including small and medium-sized enterprises as well as larger corporations, offering tools for unlimited marketing campaigns without the need for technical expertise. Additionally, the platform provides developers with an API for seamless integration into existing systems, enhancing its usability across various business models.

Gense Technologies

Seed Round in 2024
Gense Technologies is an innovative company that has created a portable and affordable self-help medical imaging device aimed at preventive screening and monitoring of chronic diseases, such as those affecting the liver, lungs, and kidneys. Designed for both home and clinical use, the device allows users to perform self-administered scans without the need for extensive training. The results are provided through an app powered by cloud-based machine learning algorithms, facilitating telemedicine applications. The company, founded by a team of 15 PhDs and researchers from prestigious institutions, is actively engaged in clinical trials and engineering partnerships. Gense has successfully secured over USD 3 million in funding and holds medical device certifications, enabling mass production of its technology. Their devices are already deployed in public hospitals for remote monitoring, including the tracking of recovered COVID-19 patients. Gense has attracted interest from healthcare distributors in over 20 global markets, aiming to establish local deployment channels in collaboration with private hospitals, clinic networks, health insurers, and multinational corporations.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.